Company intelligence / Profile preview
VelaVigo
Shanghai, Chinavelavigo.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
VelaVigo has built a robust pipeline of novel multi-specific biologics. Its lead asset, a first-in-class bispecific antibody (VBS-102), was outlicensed ex-China to Ollin Biosciences in a deal worth up to $440 million. Another major deal with Avenzo Therapeutics for a Nectin4/TROP2 bispecific ADC could reach $750 million if all milestones are met. The company raised $50M in pre-A funding in February 2025 and plans to initiate US clinical trials for its lead program within the year[3][5][6].
- Therapeutic areas
- Oncology
- Modalities
- Multi-specific antibodiesBispecific antibodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Ollin Biosciences (out-license of VBS-102)[3][5]Avenzo Therapeutics (out-license of Nectin4xTROP2 bispecific ADC)[3][5]
Beyond the preview
Go deeper on VelaVigo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VelaVigo.